文献速递垂体与肾上腺疾病

靶向垂体的塞利西利布治疗库欣病

Treatment of Cushing Disease With Pituitary-Targeting Seliciclib.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

两项前瞻性开放标签2期试验在垂体中心纳入成人库欣病患者,口服塞利西利布400 mg每日两次、每周连续4天共4周。平均24小时尿游离皮质醇(UFC)从基线226.4 ± 140.3 µg/24小时降至研究结束时131.3 ± 114.3 µg/24小时,降幅42%;3例UFC降低≥50%,2例降低48%,无一例UFC正常化。部分患者出现肝酶升高、贫血、肌酐升高及肝相关严重不良事件,停药后缓解;最低有效剂量尚需进一步确定。

要点

  • 塞利西利布可使库欣病患者平均UFC较基线降低42%,但无一例UFC正常化。
  • 3例UFC降低≥50%(范围55%-75%),2例降低48%;达到≥48%降幅者血浆ACTH降低19%(P = 0.01)。
  • 3例出现≤2级肝酶升高、贫血和/或肌酐升高,2例出现4级肝相关严重不良事件,停药后4周内缓解。

核心结论

  • 塞利西利布可能直接靶向库欣病患者的垂体促肾上腺皮质激素细胞并逆转皮质醇增多症。
  • 塞利西利布的潜在肝脏毒性在停药后缓解。
  • 最低有效剂量尚需进一步确定。

研究设计与样本

  • 两项前瞻性、开放标签、2期试验,在三级转诊垂体中心开展。
  • 纳入成人新发、持续或复发性库欣病患者,口服塞利西利布400 mg每日两次,每周连续4天,共4周。
  • 概念验证单中心研究的主要终点为研究结束时24小时尿游离皮质醇(UFC)正常化(≤ 50 µg/24小时)。
  • 试点多中心研究的主要终点为研究结束时UFC正常化或UFC较基线降低≥ 50%。
  • 16例患者签署知情同意,9例接受治疗。

主要发现

  • 平均UFC从基线226.4 ± 140.3 µg/24小时降至研究结束时131.3 ± 114.3 µg/24小时,降幅42%。
  • 纵向模型显示从基线至每个治疗周UFC均显著降低。
  • 3例患者UFC降低≥ 50%(范围55%-75%),2例患者UFC降低48%,无一例实现UFC正常化。
  • 在UFC降低≥ 48%的患者中,血浆ACTH降低19%(P = 0.01)。
  • 3例患者出现≤ 2级肝酶升高、贫血和/或肌酐升高,经中断/减量后缓解;2例患者出现4级肝相关严重不良事件,停药后4周内缓解。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 16例患者签署知情同意,仅9例接受治疗。
  • 无一例患者实现UFC正常化。
  • 最低有效剂量尚需进一步确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Preclinical studies show seliciclib (R-roscovitine) suppresses neoplastic corticotroph proliferation and pituitary adrenocorticotrophic hormone (ACTH) production. OBJECTIVE: To evaluate seliciclib as an effective pituitary-targeting treatment for patients with Cushing disease (CD). METHODS: Two prospective, open-label, phase 2 trials, conducted at a tertiary referral pituitary center, included adult patients with de novo, persistent, or recurrent CD who received oral seliciclib 400 mg twice daily for 4 consecutive days each week for 4 weeks. The primary endpoint in the proof-of-concept single-center study was normalization of 24-hour urinary free cortisol (UFC; ≤ 50 µg/24 hours) at study end; in the pilot multicenter study, primary endpoint was UFC normalization or ≥ 50% reduction in UFC from baseline to study end. RESULTS: Sixteen patients were consented and 9 were treated. Mean UFC decreased by 42%, from 226.4 ± 140.3 µg/24 hours at baseline to 131.3 ± 114.3 µg/24 hours by study end. Longitudinal model showed significant UFC reductions from baseline to each treatment week. Three patients achieved ≥ 50% UFC reduction (range, 55%-75%), and 2 patients exhibited 48% reduction; none achieved UFC normalization. Plasma ACTH decreased by 19% (P = 0.01) in patients who achieved ≥ 48% UFC reduction. Three patients developed grade ≤ 2 elevated liver enzymes, anemia, and/or elevated creatinine, which resolved with dose interruption/reduction. Two patients developed grade 4 liver-related serious adverse events that resolved within 4 weeks of seliciclib discontinuation. CONCLUSION: Seliciclib may directly target pituitary corticotrophs in CD and reverse hypercortisolism. Potential liver toxicity of seliciclib resolves with treatment withdrawal. The lowest effective dose requires further determination.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Liu NA, Ben-Shlomo A, Carmichael JD, et al. Treatment of Cushing Disease With Pituitary-Targeting Seliciclib. J Clin Endocrinol Metab. 2023. PMID: 36214832. doi:10.1210/clinem/dgac588

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。